UnitedHealth (UNH), the largest U.S. health insurer, has received a “Perfect 10” Smart Score from TipRanks. This AI-powered system combines analyst ratings, insider activity, technical indicators, and fundamental data to rate stocks from 1 to 10. A score of 10 is the highest possible and suggests the stock is likely to outperform the market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
This top score reflects strong analyst support, hedge fund buying, and solid fundamentals for UNH stock. Even so, shares are still down 38% this year, pressured by rising medical costs, a weaker Q2 performance, and a Department of Justice probe into its Medicare Advantage practices.
Buffett Bets Big on UnitedHealth
In Q2 2025, Warren Buffett’s Berkshire Hathaway (BRK.A) (BRK.B) took a $1.6 billion stake in UnitedHealth, acquiring about 5 million shares. This vote of confidence sparked a 12–14% surge in UNH stock and signaled optimism about its longer-term outlook.
Notably, billionaire investors Michael Burry and David Tepper also raised their exposure to UNH during the quarter, further boosting hopes for a turnaround.
Dividend Approval Boosts Investor Confidence
Last month, UnitedHealth’s board approved its next quarterly dividend of $2.10 per share, payable on September 23, 2025, to shareholders of record as of September 15. The decision highlights the company’s focus on steady shareholder returns.
It must be noted that UnitedHealth has now delivered more than 15 years of consistent dividends, showing its ability to return cash even in times of pressure. This steady payout helps balance investor concerns during a volatile period.
Analysts Stay Bullish Despite Challenges
Analysts continue to show confidence in UnitedHealth’s long-term outlook. Morgan Stanley analyst Erin Wright recently reiterated a Buy rating, pointing to earnings potential in 2027 as margins improve across businesses.
Mizuho analyst Ann Hynes also maintained a Buy stance, though she trimmed her price target to $300 from $350. She believes that UnitedHealth’s scale, market position, and diversified business model make it a strong player. Hynes also contends that the shares are attractively valued at the current levels.
Together, these ratings reflect Wall Street’s confidence that the company can recover in the medium term.
What Is the Future of UNH Stock?
Turning to Wall Street, UNH stock has a Strong Buy consensus rating based on 17 Buys, two Holds, and one Sell assigned in the last three months. At $314.95, the average UnitedHealth stock price target implies a 1.64% upside potential.
